RxDoctor Payments Data

Konrad Bakker, MD

Sleep Medicine · Frederick, MDNPI 1346246782

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 496 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,985 and has fallen 77.5% since, to $446 in 2025. Among sleep medicine clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,065in general payments, 2019–2025

Across 496 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$969
  • Amgen$676
  • Jazz Pharmaceuticals Inc.$672
  • Teva Pharmaceuticals USA, Inc.$478
  • Harmony Biosciences LLC$467
  • plus $4K from 50 others

What the payments were for

  • Speaking & faculty fees$421%
  • Food & beverage$7,91198%
  • Education$1131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)88$1,229
Novartis78$969
Amgen42$676
Jazz Pharmaceuticals Inc.31$672
Teva Pharmaceuticals USA, Inc.34$478
Harmony Biosciences LLC24$467
Supernus Pharmaceuticals, Inc.17$313
Lilly USA, LLC14$253
UCB, Inc.11$210
Takeda Pharmaceuticals U.S.A., Inc.9$165
Biogen7$156
Lundbeck LLC7$151
Sanofi7$144
Eisai Inc.8$139
AstraZeneca8$135
Arbor Pharmaceuticals, Inc.8$118
Biohaven Pharmaceuticals, Inc.9$111
Upsher-smith Laboratories LLC6$103
Bristol Myers Squibb6$100
Pfizer5$90
EMD Serono, Inc.5$87
Resmed Corp5$83
Axsome Therapeutics, Inc.3$79
Promius Pharma LLC4$76
Merck5$73
Amneal Pharmaceuticals LLC3$71
Avadel CNS Pharmaceuticals, LLC3$64
E.r. Squibb & Sons, L.L.C.4$59
Genentech USA, Inc.3$52
Collegium Pharmaceutical, Inc.3$49
Biohaven Pharmaceutical Holding Company Ltd.3$49
Mallinckrodt Hospital Products Inc.2$44
Livanova USA, Inc.3$44
Johnson & Johnson2$44
Avanir Pharmaceuticals, Inc.2$43
Acorda Therapeutics, Inc2$42
Alnylam Pharmaceuticals Inc.2$40
Ipsen Biopharmaceuticals, Inc2$36
Impel Pharmaceuticals Inc.2$32
Idorsia Pharmaceuticals US Inc2$32
Bausch Health US, LLC1$26
Currax Pharmaceuticals LLC2$25
Banner Life Sciences, LLC1$24
Novo Nordisk1$23
Boston Scientific1$21
Neurocrine Biosciences, Inc.1$19
Ironshore Pharmaceuticals Inc.1$18
Greenwich Biosciences, Inc.1$17
Xeris Pharmaceuticals, Inc.1$17
Almatica Pharma LLC1$16
Endo Pharmaceuticals Inc.1$15
Acadia Pharmaceuticals Inc1$15
Vanda Pharmaceuticals Inc.1$15
Philips North America LLC1$12
Sanofi-aventis U.S. LLC1$12
Fisher & Paykel Healthcare Inc1$11

How this compares

$8,065 in reported general payments places this provider in the 90th percentile of 41 sleep medicine providers in Maryland.

See all sleep medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$227,461
Medicare patients
1,220
Services billed
1,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SunosiSolriamfetol Hcl41$53,248
Modafinil187$28,111
Emgality PenGalcanezumab-Gnlm17$17,791
Aimovig AutoinjectorErenumab-Aooe15$15,007
Nurtec OdtRimegepant Sulfate13$12,903
Armodafinil95$12,375
Eszopiclone214$8,402
BelsomraSuvorexant11$7,768
Zolpidem Tartrate ErZolpidem Tartrate83$4,932
Zolpidem Tartrate285$3,683
Doxepin Hcl33$3,625
Sumatriptan Succinate22$2,565
Estazolam25$2,185
Triazolam20$1,766
Gabapentin34$1,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Sunosi$79$53,24841 claims
PfizerNurtec Odt$90$12,90313 claims
MerckBelsomra$73$7,76811 claims
Upsher-smith Laboratories LLCTopiramate$103$35018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 41 sleep medicine providers in Maryland.

Other sleep medicine in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →